Market Forecast Reports
SEE OTHER BRANDS

Top market forecasts news from the world

Market Forecast Reports: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Market Forecast Reports.

Press releases published on June 15, 2025

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Iovance Biotherapeutics, Inc.(IOVA) Shareholders

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Iovance Biotherapeutics, Inc.(IOVA) Shareholders

NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) -- Levi …

HAPPY FATHER’S DAY! and $HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of M2i Global, Inc. (OTCQB: MTWO) 

HAPPY FATHER’S DAY! and $HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of M2i Global, Inc. (OTCQB: MTWO) 

NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde …

CGTN: From father to son: The enduring values guiding Xi Jinping

CGTN: From father to son: The enduring values guiding Xi Jinping

BEIJING, June 15, 2025 (GLOBE NEWSWIRE) -- During a 2021 visit to the very place where his father had once worked, Chinese President Xi Jinping softly recited a line now displayed prominently in the exhibition hall – "Sit upright at the side of the people …

CAR FINAL DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Avis Budget Group, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 24 Deadline in Securities Class Action - CAR

CAR FINAL DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Avis Budget Group, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 24 Deadline in Securities Class Action - CAR

NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Avis Budget Group, Inc. (NASDAQ: CAR) between February 16, 2024 and February 10, 2025, both dates inclusive (the “Class …

CAR 截止日期提醒:廣受信賴的投資人法律顧問 ROSEN 鼓勵損失超過 10 萬美元的 Avis Budget Group, Inc 投資人於 6 月 24 日證券集體訴訟重要截止日期前聘請律師 - CAR

CAR 截止日期提醒:廣受信賴的投資人法律顧問 ROSEN 鼓勵損失超過 10 萬美元的 Avis Budget Group, Inc 投資人於 6 月 24 日證券集體訴訟重要截止日期前聘請律師 - CAR

紐約, June 15, 2025 (GLOBE NEWSWIRE) -- 事由:全球投資人權益律師事務所 Rosen Law Firm 提醒在 2024 年 2 月 16 日至 2025 年 2 月 10 日(含首尾兩天,簡稱「集體訴訟期間」)期間購買 Avis Budget Group, Inc. (NASDAQ: CAR) 股票的人士,2025 年 6 月 24 日是重要的首席原告截止日期。 影響性:倘若您在集體訴訟期內曾購買 Avis Budget …

XRP Ledger Payment Volume Skyrockets Over 1,000%, Analysts Expect Similar For Remittix (RTX)

XRP Ledger Payment Volume Skyrockets Over 1,000%, Analysts Expect Similar For Remittix (RTX)

New York, June 15, 2025 (GLOBE NEWSWIRE) -- Surprises are common in the crypto sphere but an unprecedented 1,000% surge in XRP Ledger’s payment volume hits different. It speaks of marvelous things to come. That’s why investors are scrambling to position …

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study

EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study New late-breaking data at EAACI showed Dupixent …

Communiqué :  Dupixent a démontré sa supériorité par rapport au Xolair dans la rhinosinusite chronique avec polypes nasaux chez des patients atteints d’asthme coexistant dans la toute 1ere étude respiratoire de ph4 en comparaison directe …

Communiqué : Dupixent a démontré sa supériorité par rapport au Xolair dans la rhinosinusite chronique avec polypes nasaux chez des patients atteints d’asthme coexistant dans la toute 1ere étude respiratoire de ph4 en comparaison directe …

EAACI : Le Dupixent a démontré sa supériorité par rapport au Xolair (omalizumab) dans la rhinosinusite chronique avec polypes nasaux chez des patients atteints d’asthme coexistant dans la toute première étude respiratoire de phase 4 en comparaison directe …

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4 Head-to-Head Respiratory Trial

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4 Head-to-Head Respiratory Trial

New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints Dupixent also outperformed Xolair in improving such key signs and symptoms as nasal polyp …

Napco (NSSC) Under Scrutiny: Investor Suit and Sales Slump Shake Investor Confidence – Hagens Berman

Napco (NSSC) Under Scrutiny: Investor Suit and Sales Slump Shake Investor Confidence – Hagens Berman

SAN FRANCISCO, June 15, 2025 (GLOBE NEWSWIRE) -- Shares in Napco Security Technologies, Inc. (NASDAQ: NSSC) are trading down nearly 21% year-to-date, as the security technology company continues to face heightened scrutiny as it navigates both legal and …

IBTA FINAL DEADLINE: ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Ibotta, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 16 Deadline in Securities Class Action First Filed by the Firm – IBTA

IBTA FINAL DEADLINE: ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Ibotta, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 16 Deadline in Securities Class Action First Filed by the Firm – IBTA

NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Ibotta, Inc. (NYSE: IBTA): (1) pursuant and/or traceable to the registration statement and related prospectus ( …

IBTA 最終截止日期:享譽全球的律師事務所 ROSEN 鼓勵損失超過 10 萬美元的 Ibotta, Inc. 投資者在該事務所對 IBTA 首次提出證券集體訴訟之重要截止日期 6 月 16 日前聘請律師

IBTA 最終截止日期:享譽全球的律師事務所 ROSEN 鼓勵損失超過 10 萬美元的 Ibotta, Inc. 投資者在該事務所對 IBTA 首次提出證券集體訴訟之重要截止日期 6 月 16 日前聘請律師

紐約, June 15, 2025 (GLOBE NEWSWIRE) -- 事因:全球投資者權益律師事務所 Rosen Law Firm 提醒:(1) 根據及/或可追溯至因 Ibotta, Inc.(NYSE: IBTA)於 2024 年 4 月 18 日進行首次公開招股(簡稱「IPO」)所發行之註冊聲明及相關招股章程(統稱「註冊聲明」)而購買該公司證券之人士;或 (2) 於 2024 年 4 月 18 日至 2025 年 2 月 26 …

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress

With up to three years of follow-up, a single dose of lonvo-z led to a 98% mean reduction in monthly HAE attack rate in all 10 patients All 10 patients were attack-free and treatment-free for a median of 23 months through the latest follow-up, …

WST IMPORTANT DEADLINE: ROSEN, NATIONAL TRIAL COUNSEL, Encourages West Pharmaceutical Services, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – WST

WST IMPORTANT DEADLINE: ROSEN, NATIONAL TRIAL COUNSEL, Encourages West Pharmaceutical Services, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – WST

NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of West Pharmaceutical Services, Inc. (NYSE: WST) between February 16, 2023 and February 12, 2025, both dates inclusive ( …

WST 重要截止日期:全美審訊法律顧問 ROSEN 鼓勵損失 10 萬美元以上的 West Pharmaceutical Services, Inc. 投資者在對 WST 提出證券集體訴訟的重要截止日期前聘請律師

WST 重要截止日期:全美審訊法律顧問 ROSEN 鼓勵損失 10 萬美元以上的 West Pharmaceutical Services, Inc. 投資者在對 WST 提出證券集體訴訟的重要截止日期前聘請律師

紐約, June 15, 2025 (GLOBE NEWSWIRE) -- 事因:全球投資者權益律師事務所 Rosen Law Firm 提醒在 2023 年 2 月 16 日至 2025 年 2 月 12 日(包括首尾兩日,下稱「集體訴訟期」)期間購買了 West Pharmaceutical Services, Inc. (NYSE: WST) 普通股之人士注意,重要的首席原告截止日期為 2025 年 7 月 7 日。 影響:如果您在集體訴訟期間購買 West …

Study indicates Germany losing industrial jobs

Study indicates Germany losing industrial jobs

(MENAFN) Germany’s industrial sector has cut more than 100,000 jobs over the past year as the country’s economic downturn deepens, according to a study by consultancy EY, cited by the German Press Agency (dpa). The hardest-hit industry was the automotive …

Gold surpasses euro in international reserves

Gold surpasses euro in international reserves

(MENAFN) Gold has overtaken the euro to become the world’s second-largest reserve asset by market value, according to the European Central Bank (ECB). The change reflects record buying by central banks and growing geopolitical tensions. In 2024, central …

Reputation Pros Named Best Online Reputation Management Company of 2025 by Modern Luxury Magazine

Reputation Pros Named Best Online Reputation Management Company of 2025 by Modern Luxury Magazine

Miami, FL, June 15, 2025 (GLOBE NEWSWIRE) -- Modern Luxury Magazine today announced Reputation Pros as the best online reputation management company of 2025 in its annual Best Online Reputation Management Companies feature, published online in May 2025. …

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NWTN Inc. - NWTN

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NWTN Inc. - NWTN

NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  NWTN Inc. (“NWTN” or the “Company”) (NASDAQ: NWTN).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, …

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc.  - SMMT

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc.  - SMMT

NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Summit Therapeutics Inc. (“Summit” or the “Company”) (NASDAQ: SMMT).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service